London, UK / New York, USA – In a discovery poised to significantly reshape our understanding of cancer progression and patient prognosis, an international consortium of researchers has unveiled a critical link between age-related genetic changes in blood cells and the severity of cancerous tumours. Scientists from the Francis Crick Institute, University College London (UCL), Gustave Roussy, and Memorial Sloan Kettering Cancer Center (MSK) have found that the expansion of mutant blood cells, a phenomenon commonly associated with ageing, can infiltrate solid tumours, leading to demonstrably worse outcomes for patients across various cancer types.
This landmark finding, published today in the prestigious New England Journal of Medicine, introduces a new concept: "tumour infiltrating clonal haematopoiesis" (TI-CH). It highlights how systemic, age-related cellular changes, previously known to increase the risk of conditions like cardiovascular disease, play a direct and detrimental role in cancer evolution. The research indicates that TI-CH is not merely a co-occurrence but an active contributor to tumour aggression, relapse, and ultimately, patient mortality, independent of factors like age or initial cancer stage. The implications are profound, offering new avenues for prognostic assessment and potentially for therapeutic intervention against some of the most challenging cancers.
The Silent Threat of Ageing Cells: Unravelling Clonal Haematopoiesis
Understanding the intricate biological interplay between age-related genetic shifts and the diseases that often accompany ageing, such as cancer and cardiovascular disease, is paramount for developing effective preventative and therapeutic strategies for our increasingly elderly global population. One such age-related phenomenon is Clonal Haematopoiesis of Indeterminate Potential (CHIP).
CHIP is a condition where blood stem cells accumulate specific genetic mutations over time. While the term "indeterminate potential" suggests a state where these mutations haven’t yet caused a blood cancer, they represent a significant deviation from normal cellular function. Influenced by both the natural march of ageing and various external environmental factors (such as exposure to certain toxins or chronic inflammation), these mutated stem cells gain a competitive advantage, leading to their disproportionate expansion within the bone marrow. This "clonal expansion" means that a growing fraction of a person’s blood cells, including red blood cells, white blood cells, and platelets, originate from these mutated progenitors.
Prior research had already firmly established CHIP as a risk factor for a spectrum of age-related disorders, most notably cardiovascular disease. It has been linked to increased inflammation, arterial plaque buildup, and a higher incidence of heart attacks and strokes. However, the precise impact of these age-related genetic alterations in the blood on the evolution and aggressiveness of solid cancers – tumours originating in organs like the lung, pancreas, or breast – had remained largely unexplored until now. This new study fills a crucial gap, demonstrating that the influence of CHIP extends far beyond blood and cardiovascular health, directly impacting the trajectory of solid tumour malignancies.
A Rigorous Scientific Journey: Tracing the Link
The path to this pivotal discovery involved a multi-faceted approach, combining extensive clinical data analysis with detailed molecular and experimental investigations. The research team meticulously examined an unprecedented volume of patient data, initially focusing on two prominent UK-based cancer studies: TRACERx and PEACE.
The TRACERx (Tracking Cancer Evolution through therapy) study, funded by Cancer Research UK, is a groundbreaking longitudinal study following thousands of lung cancer patients from diagnosis through treatment and beyond. Its primary aim is to understand how lung tumours evolve, adapt to therapy, and develop resistance, by analysing tumour biopsies taken at multiple time points. The PEACE (Postmortem rEsearch cAncer Evolution) study, also funded by Cancer Research UK, complements TRACERx by performing rapid post-mortem investigations of patients who have succumbed to cancer. This unique approach allows researchers to study metastatic sites – the areas where cancer has spread – which are often the ultimate cause of patient death, providing invaluable insights into the final stages of cancer evolution.
These two studies provided the initial, in-depth cohort of over 400 lung cancer patients for the current investigation. The researchers leveraged the extensive clinical and genomic data collected within TRACERx and PEACE to identify patients with CHIP and correlate this with their cancer outcomes.
Subsequently, to validate and broaden their findings, the team collaborated with researchers at Memorial Sloan Kettering Cancer Center (MSK) in the United States. This collaboration provided access to an even larger and more diverse dataset, encompassing over 49,000 patients with a wide array of different cancer types. This extensive validation cohort was critical for establishing the generalizability and robustness of the initial observations made in lung cancer.
The methodological journey unfolded in several key stages:
- Initial Blood Sample Analysis: Researchers first analysed blood samples from the lung cancer patients to identify the presence of CHIP mutations. Using advanced genomic sequencing techniques, they screened for common CHIP-associated gene alterations in the circulating blood cells.
- Clinical Data Matching: The identified CHIP status was then meticulously matched with comprehensive clinical data for each patient, including their age at diagnosis, the stage of their cancer, and crucially, their overall survival duration.
- Detailed Tumour Infiltration Study: The team then delved deeper, examining tumour biopsies from CHIP-positive patients. Their goal was to determine whether the blood cells carrying these CHIP mutations had physically infiltrated the lung tumours. This led to the discovery of "tumour infiltrating clonal haematopoiesis" (TI-CH).
- Post-Mortem Confirmation: Samples from the PEACE study were invaluable here. By examining metastatic tumours from deceased patients, the researchers confirmed the presence of TI-CH mutations in these aggressive, treatment-resistant sites, reinforcing its link to advanced disease.
- Cellular Composition Analysis: To understand the functional consequences of TI-CH, the scientists analysed the cellular makeup of the lung tumours. They specifically looked for changes in the immune cell populations within the tumour microenvironment.
- Genetic Mutation Focus: The investigation pinpointed specific genetic mutations, particularly in the TET2 gene, which appeared to be key drivers of the observed phenomena.
- Experimental Validation: Finally, the team moved from correlation to causation through experimental work. They developed sophisticated organoid models – mini lung tumours – and introduced TET2-mutant myeloid cells to observe their direct impact on tumour growth and the surrounding microenvironment.
This comprehensive, multi-stage approach, spanning large-scale clinical cohorts to intricate laboratory experiments, provided compelling evidence for the novel role of age-related blood cell mutations in cancer progression.
Supporting Data and Mechanisms: Unpacking the "How" and "Why"
The research yielded a wealth of supporting data that meticulously detailed the impact of CHIP and TI-CH on cancer prognosis and elucidated the underlying biological mechanisms.
The CHIP-Cancer Link Deepened: From Correlation to Critical Factor
An initial, broad examination of the blood samples confirmed the presence of CHIP mutations in a significant proportion of the study population. When these findings were correlated with extensive clinical data, a concerning pattern emerged: patients with CHIP mutations in their blood exhibited a shorter overall survival period. Crucially, this association remained significant even after accounting for other major prognostic factors such as the patient’s age at diagnosis and the initial stage of their cancer. This indicated that CHIP was an independent predictor of poorer outcomes, suggesting it was not merely a bystander effect of ageing or advanced disease, but a distinct biological factor influencing prognosis.
However, the team’s subsequent, more granular analysis revealed an even more critical distinction. They found that while CHIP was associated with worse outcomes, it was specifically the presence of Tumour Infiltrating Clonal Haematopoiesis (TI-CH) – where CHIP-mutated blood cells had physically infiltrated the tumour mass – that was the dominant factor driving the increased risk of cancer relapse and cancer-related death. This was observed in 42% of patients who initially presented with CHIP mutations. This distinction is vital: simply having CHIP in the blood might indicate a general predisposition, but its direct engagement within the tumour microenvironment appears to be the true harbinger of aggressive disease.
Further corroborating this finding, samples from the PEACE study provided invaluable insights into metastatic disease, which is the primary cause of cancer-related mortality. The team discovered that these highly aggressive, metastatic tumours, often located at distant sites from the primary tumour, frequently contained TI-CH mutations. This strong correlation between TI-CH and metastatic spread underscored its profound impact on the most lethal aspect of cancer.
The Tumour Microenvironment: A Battleground Remodelled by Mutant Cells
To understand how TI-CH exerts its detrimental effects, the scientists turned their attention to the composition of cells within the lung tumours. They found a consistent pattern in patients with TI-CH: a significant expansion of myeloid cells, a specific type of immune cell, within the tumour microenvironment (TME).
The tumour microenvironment is a complex ecosystem surrounding cancer cells, comprising various non-cancerous cells (immune cells, fibroblasts, endothelial cells), blood vessels, and signalling molecules. It plays a critical role in determining tumour growth, invasion, metastasis, and response to therapy. While some immune cells, such as cytotoxic T lymphocytes, are primed to recognise and eliminate cancer cells, myeloid cells often exhibit a more ambivalent or even pro-tumour role.
Unlike some beneficial immune cells, myeloid cells have been extensively shown to regulate inflammation and can actively support tumour progression and spread. In the context of cancer, certain myeloid cell subsets, such as myeloid-derived suppressor cells (MDSCs) and tumour-associated macrophages (TAMs), can suppress anti-tumour immune responses, promote angiogenesis (new blood vessel formation to feed the tumour), facilitate tumour cell invasion, and even contribute to chemotherapy resistance. The observed expansion of myeloid cells in TI-CH patients therefore presented a compelling mechanistic link: these age-related mutant blood cells were altering the TME in a way that directly favoured cancer growth and aggression.
The TET2 Gene: A Key Driver of Pathological Myeloid Function
The researchers then sought to identify the specific genetic mutations within the CHIP-affected blood cells that were most responsible for this pro-tumourigenic shift. Their analysis, across thousands of individuals, pointed to mutations affecting a gene called TET2. The TET2 gene is a crucial regulator of blood cell production and function, playing a vital role in epigenetic modification – processes that control gene expression without altering the underlying DNA sequence. Mutations in TET2 are commonly found in CHIP and are known to disrupt normal haematopoiesis.
The study revealed that when TET2 was mutated, the blood cells carrying these mutations were significantly more likely to infiltrate tumours. To confirm which specific cell types were harbouring these mutations within the tumour, the team performed single-cell analysis on hundreds of individual cells isolated from the tumours of two patients with TI-CH. This high-resolution analysis definitively showed that TET2 mutations were predominantly present in myeloid cells, and not in other immune cell types, solidifying the link between TET2 dysfunction, myeloid cell infiltration, and cancer.
To move beyond mere correlation and establish a causal link, the research team collaborated with experts in blood cancer and CHIP, led by Dominique Bonnet at the Crick Institute. They conducted elegant experimental studies using organoids – three-dimensional mini-tumours grown in the lab that faithfully recapitulate key features of human tumours. By co-culturing these lung tumour organoids with TET2-mutant myeloid cells, they observed a dramatic effect: the TET2-mutant myeloid cells actively remodelled the tumour microenvironment and significantly accelerated the growth of the tumour organoids. This experimental validation provided powerful evidence that TET2-mutant myeloid cells are not just bystanders but active participants in driving tumour progression.
Broader Validation Across Cancer Types: A Universal Threat?
The final, crucial step in this comprehensive study involved validating the findings across a much broader spectrum of cancers. In collaboration with MSK, the team analysed data from over 49,000 patients with diverse cancer types. The results were striking: the presence of TI-CH consistently emerged as an independent predictor of shorter survival, regardless of the specific cancer type. This underscored the widespread applicability and clinical significance of their discovery.
While TI-CH was broadly detrimental, the prevalence of both CHIP and TI-CH varied considerably between different cancer types. Researchers observed these mutations to be more common in cancers notoriously difficult to treat, such as lung cancer (the initial focus), head and neck cancer, and pancreatic cancer. This differential prevalence suggests that the interaction between age-related haematopoietic changes and tumour progression might be particularly potent in certain aggressive malignancies, potentially contributing to their recalcitrance to standard therapies. This observation opens new avenues for investigating why certain cancers are inherently more challenging to manage and how TI-CH might exacerbate these difficulties.
Official Responses and Expert Commentary: A New Paradigm for Ageing and Cancer
The significance of these findings was immediately recognized by the lead researchers and clinical experts.
Dr. Oriol Pich, a Postdoctoral Project Research Scientist in the Crick’s Cancer Evolution and Genome Instability Laboratory and a lead author on the study, emphasized the direct implications of the discovery: "Our results show that blood cells carrying age-related mutations can infiltrate tumours and impact cancer evolution, leading to worse outcomes for patients. This is important because CHIP is a natural phenomenon of ageing that is common in patients with cancer. Given the increasing global ageing population, understanding this interplay becomes ever more critical for patient management."
Professor Charlie Swanton, Deputy Clinical Director at the Crick, Chief Clinician at Cancer Research UK, and Chief Investigator for TRACERx, highlighted the novelty and conceptual shift represented by this work: "This is the first time that we’ve been able to see at scale, the interaction of two different types of ‘clonal proliferations,’ age-related CHIP and cancer, providing unprecedented insight into how ageing might impact cancer risk and progression. Traditionally, we’ve viewed cancer largely as a localized disease, but this research underscores how systemic, age-related changes can profoundly influence its trajectory."
Professor Swanton further articulated the broader implications for future medical strategies: "As we start to piece together the picture of the most important mutations which evolve during the ageing process in cells from the bone marrow, and the impact they have in disease, we hope we can start to identify opportunities for intervention and maybe even prevention of some age-related cancers. This work truly opens up a new frontier, bridging the fields of gerontology, haematology, and oncology to develop more holistic approaches to cancer care."
The research was made possible through the generous support of key funders, including Cancer Research UK and the National Institute of Health and Care Research UCLH Biomedical Research Centre, alongside additional funders, underscoring the collaborative effort required for such a monumental scientific undertaking. The interdisciplinary nature of the study, involving experts in cancer evolution, genomics, immunology, and haematology, exemplifies the integrated approach necessary to tackle complex biological challenges.
Implications and Future Directions: Towards New Diagnostics and Therapies
The discovery of TI-CH represents a significant leap forward in our understanding of cancer, carrying substantial implications for both clinical practice and future research.
Clinical Implications: Refining Prognosis and Stratifying Treatment
The most immediate clinical implication is the potential for TI-CH to serve as a powerful new prognostic biomarker. Identifying TI-CH in cancer patients could allow clinicians to more accurately identify individuals at a higher risk of relapse and shorter survival, independent of traditional staging methods. This could lead to more precise patient stratification, enabling doctors to tailor treatment strategies more effectively. For instance, patients with TI-CH might warrant more aggressive upfront therapies, closer monitoring for recurrence, or consideration for novel experimental treatments.
Routine screening for CHIP mutations in cancer patients, particularly those with lung, head and neck, or pancreatic cancers, could become a standard part of diagnostic workup. If CHIP is detected, further investigation for tumour infiltration (TI-CH) could then guide personalized medicine approaches, ensuring that high-risk patients receive the most appropriate and intensive care from the outset. This could also inform post-treatment surveillance protocols, allowing for earlier detection of relapse.
Therapeutic Opportunities: Targeting the Pro-Tumour Environment
The mechanistic insights provided by this study also open exciting new avenues for therapeutic development. If TET2-mutant myeloid cells are indeed key drivers of tumour aggression by remodelling the microenvironment, then directly targeting these cells or their pro-tumour functions could represent a novel therapeutic strategy.
Potential interventions could include:
- Immunomodulatory Drugs: Therapies aimed at re-educating or depleting the pro-tumourigenic myeloid cell populations within the TME.
- Epigenetic Therapies: Drugs that specifically target the epigenetic dysregulation caused by TET2 mutations, potentially restoring normal myeloid cell function and reducing their tumour-promoting effects.
- Combination Therapies: Integrating therapies that address TI-CH with existing anti-cancer treatments (chemotherapy, immunotherapy, targeted therapy) to enhance overall efficacy and overcome resistance.
Beyond direct intervention, strategies aimed at preventing the infiltration of these mutant blood cells into tumours, or at reversing the remodelling of the TME they induce, could also be explored.
Research Frontier: Unravelling Causation and Broader Impact
While this study establishes a strong association and provides compelling mechanistic evidence, the next critical steps will involve confirming the direct causal contribution of CHIP to cancer outcomes and detailing the exact molecular mechanisms by which CHIP functionally implicates itself in the development of aggressive cancers. This will involve more sophisticated preclinical models and further longitudinal studies.
This research also has broader implications for our understanding of ageing and age-related diseases. By demonstrating a direct link between age-related clonal haematopoiesis and cancer progression, it reinforces the concept that ageing is not merely a risk factor for disease, but an active process that can drive pathological changes across multiple organ systems. This will necessitate greater interdisciplinary collaboration between cancer biologists, immunologists, haematologists, and gerontologists to develop comprehensive strategies for healthy ageing and disease prevention.
Despite the complexities of the tumour microenvironment and the inherent variability across different cancer types, this groundbreaking research offers a beacon of hope. By identifying TI-CH as a critical, previously unappreciated factor in cancer prognosis, scientists are now better equipped to develop more effective diagnostics and innovative therapeutic strategies, ultimately improving outcomes for a growing number of cancer patients worldwide. The journey has just begun, but the path towards a more profound understanding of ageing’s role in cancer, and how to counteract its detrimental effects, is now clearer than ever before.
About the Author
